953079-96-4 Usage
Description
Ethyl N-Cbz-3-piperidineacetate is a chemical compound that is commonly used in organic synthesis and pharmaceutical research. It is a derivative of piperidine, a heterocyclic compound that is found in a variety of natural products and synthetic drugs. The "N-Cbz" group in the compound's name refers to the presence of a carbobenzyloxy (Cbz) protecting group, which can be removed under specific reaction conditions. Ethyl N-Cbz-3-piperidineacetate has potential applications in the development of novel drugs and therapeutic agents, as well as in the production of complex organic molecules through chemical synthesis. Its unique structure and reactivity make it a valuable tool for chemists and researchers working in the field of organic chemistry.
Uses
Used in Pharmaceutical Research:
Ethyl N-Cbz-3-piperidineacetate is used as an intermediate in the synthesis of various pharmaceutical compounds for the development of novel drugs and therapeutic agents.
Used in Organic Synthesis:
Ethyl N-Cbz-3-piperidineacetate is used as a building block in the production of complex organic molecules through chemical synthesis, providing a versatile and valuable tool for chemists and researchers in the field of organic chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 953079-96-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,3,0,7 and 9 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 953079-96:
(8*9)+(7*5)+(6*3)+(5*0)+(4*7)+(3*9)+(2*9)+(1*6)=204
204 % 10 = 4
So 953079-96-4 is a valid CAS Registry Number.
953079-96-4Relevant articles and documents
2,6-SUBSTITUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
-
, (2008/06/13)
The present invention is directed to a compound of formula (I) wherein R1 and R2 are as defined herein, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, a pharmaceutically acceptable prodrug thereof, or a pharmaceutically acceptable salt, hydrate or solvate of the prodrug, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds of the invention in admixture with a pharmaceutically acceptable carrier, a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which are generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound of the invention.
